{"title":"非霍奇金淋巴瘤的治疗进展:探索新领域","authors":"T. Ibbotson","doi":"10.33590/emjhematol/10312986","DOIUrl":null,"url":null,"abstract":"A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of non-Hodgkin’s lymphoma (NHL) and the potential impact of new approaches to diagnosis and treatment. Prof Kimby opened the symposium by discussing the recent therapeutic advances in the treatment of follicular lymphoma (FL). Prof Georg Lenz then spoke about the clinical implications of diffuse large B cell lymphoma (DLBCL) diagnosis and the manner in which disease subtyping can foster effective use of targeted therapies. Prof Catherine Thieblemont presented on post-induction treatment in DLBCL, and the importance of effective treatment options to limit the number of patients who fail first-line therapy. Prof Pier Luigi Zinzani then concluded the symposium by presenting data on the new immuno-oncology treatments being evaluated in patients with relapsed or refractory NHL.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in the Treatment of Non-Hodgkin’s Lymphoma: Exploring New Frontiers\",\"authors\":\"T. Ibbotson\",\"doi\":\"10.33590/emjhematol/10312986\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of non-Hodgkin’s lymphoma (NHL) and the potential impact of new approaches to diagnosis and treatment. Prof Kimby opened the symposium by discussing the recent therapeutic advances in the treatment of follicular lymphoma (FL). Prof Georg Lenz then spoke about the clinical implications of diffuse large B cell lymphoma (DLBCL) diagnosis and the manner in which disease subtyping can foster effective use of targeted therapies. Prof Catherine Thieblemont presented on post-induction treatment in DLBCL, and the importance of effective treatment options to limit the number of patients who fail first-line therapy. Prof Pier Luigi Zinzani then concluded the symposium by presenting data on the new immuno-oncology treatments being evaluated in patients with relapsed or refractory NHL.\",\"PeriodicalId\":326555,\"journal\":{\"name\":\"EMJ Hematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjhematol/10312986\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjhematol/10312986","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
最近在欧洲血液学协会(EHA)大会上，Eva Kimby教授主持了一次研讨会，探讨了非霍奇金淋巴瘤(NHL)治疗模式的变化以及新诊断和治疗方法的潜在影响。Kimby教授首先讨论了滤泡性淋巴瘤(滤泡性淋巴瘤)治疗的最新进展。Georg Lenz教授随后谈到了弥漫性大B细胞淋巴瘤(DLBCL)诊断的临床意义，以及疾病亚型可以促进有效使用靶向治疗的方式。Catherine Thieblemont教授介绍了DLBCL的诱导后治疗，以及有效的治疗方案对于限制一线治疗失败的患者数量的重要性。Pier Luigi Zinzani教授随后介绍了在复发或难治性NHL患者中正在评估的新的免疫肿瘤学治疗方法的数据，从而结束了研讨会。
Advances in the Treatment of Non-Hodgkin’s Lymphoma: Exploring New Frontiers
A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of non-Hodgkin’s lymphoma (NHL) and the potential impact of new approaches to diagnosis and treatment. Prof Kimby opened the symposium by discussing the recent therapeutic advances in the treatment of follicular lymphoma (FL). Prof Georg Lenz then spoke about the clinical implications of diffuse large B cell lymphoma (DLBCL) diagnosis and the manner in which disease subtyping can foster effective use of targeted therapies. Prof Catherine Thieblemont presented on post-induction treatment in DLBCL, and the importance of effective treatment options to limit the number of patients who fail first-line therapy. Prof Pier Luigi Zinzani then concluded the symposium by presenting data on the new immuno-oncology treatments being evaluated in patients with relapsed or refractory NHL.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
